Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...
Background Dry needling is therapeutic approach targeting myofascial trigger points. The application of dry needling into muscle strain is a controversial clinical topic. The application of dry ...
The optimal adjuvant treatment approach for muscle-invasive bladder cancer (MIBC) remains unsettled. The IMvigor011 trial demonstrated that circulating tumor DNA (ctDNA)–guided adjuvant atezolizumab ...
The median disease-free survival was 9.9 months for the atezolizumab arm and 4.8 months for the placebo arm. In muscle-invasive bladder cancer (MIBC) patients, circulating tumor DNA (ctDNA)-guided, ...
In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results